PL2773638T3 - Związki heteroarylopirydonowe i azapirydonowe jako inhibitory aktywności btk - Google Patents

Związki heteroarylopirydonowe i azapirydonowe jako inhibitory aktywności btk

Info

Publication number
PL2773638T3
PL2773638T3 PL12783837T PL12783837T PL2773638T3 PL 2773638 T3 PL2773638 T3 PL 2773638T3 PL 12783837 T PL12783837 T PL 12783837T PL 12783837 T PL12783837 T PL 12783837T PL 2773638 T3 PL2773638 T3 PL 2773638T3
Authority
PL
Poland
Prior art keywords
pyridone
aza
inhibitors
heteroaryl
btk activity
Prior art date
Application number
PL12783837T
Other languages
English (en)
Polish (pl)
Inventor
James John Crawford
Daniel Fred Ortwine
Binqing Wei
Wendy B Young
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PL2773638T3 publication Critical patent/PL2773638T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL12783837T 2011-11-03 2012-11-02 Związki heteroarylopirydonowe i azapirydonowe jako inhibitory aktywności btk PL2773638T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161555393P 2011-11-03 2011-11-03
EP12783837.3A EP2773638B1 (en) 2011-11-03 2012-11-02 Heteroaryl pyridone and aza-pyridone compounds as inhibitors of btk activity
PCT/US2012/063194 WO2013067274A1 (en) 2011-11-03 2012-11-02 Heteroaryl pyridone and aza-pyridone compounds as inhibitors of btk activity

Publications (1)

Publication Number Publication Date
PL2773638T3 true PL2773638T3 (pl) 2016-03-31

Family

ID=47146779

Family Applications (3)

Application Number Title Priority Date Filing Date
PL12783837T PL2773638T3 (pl) 2011-11-03 2012-11-02 Związki heteroarylopirydonowe i azapirydonowe jako inhibitory aktywności btk
PL19152979T PL3521288T3 (pl) 2011-11-03 2012-11-02 Związki heteroarylopirydonowe i aza-pirydonowe jako inhibitory aktywności btk
PL15188086T PL3002284T3 (pl) 2011-11-03 2012-11-02 Związki heteroarylowe pirydonowe i aza-pirydonowe jako inhibitory aktywności btk

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL19152979T PL3521288T3 (pl) 2011-11-03 2012-11-02 Związki heteroarylopirydonowe i aza-pirydonowe jako inhibitory aktywności btk
PL15188086T PL3002284T3 (pl) 2011-11-03 2012-11-02 Związki heteroarylowe pirydonowe i aza-pirydonowe jako inhibitory aktywności btk

Country Status (34)

Country Link
US (11) US8716274B2 (en:Method)
EP (5) EP2773638B1 (en:Method)
JP (5) JP5976827B2 (en:Method)
KR (2) KR101659193B1 (en:Method)
CN (2) CN107011348B (en:Method)
AR (2) AR088641A1 (en:Method)
AU (5) AU2012332365B2 (en:Method)
CA (1) CA2853975C (en:Method)
CL (1) CL2014001103A1 (en:Method)
CO (1) CO6950472A2 (en:Method)
CR (1) CR20140194A (en:Method)
CY (1) CY1117097T1 (en:Method)
DK (2) DK3002284T3 (en:Method)
EA (1) EA023263B1 (en:Method)
ES (3) ES2738329T3 (en:Method)
HR (2) HRP20151442T1 (en:Method)
HU (2) HUE028019T2 (en:Method)
IL (1) IL232060A (en:Method)
IN (1) IN2014CN03250A (en:Method)
LT (1) LT3002284T (en:Method)
MA (1) MA35819B1 (en:Method)
MX (2) MX2014005331A (en:Method)
PE (1) PE20141586A1 (en:Method)
PH (1) PH12014500936A1 (en:Method)
PL (3) PL2773638T3 (en:Method)
PT (2) PT2773638E (en:Method)
RS (2) RS54505B1 (en:Method)
SG (1) SG11201401992YA (en:Method)
SI (2) SI2773638T1 (en:Method)
TR (1) TR201909849T4 (en:Method)
TW (4) TWI609868B (en:Method)
UA (1) UA111756C2 (en:Method)
WO (1) WO2013067274A1 (en:Method)
ZA (1) ZA201804727B (en:Method)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12014500966A1 (en) * 2011-11-03 2014-06-09 Hoffmann La Roche Alkylated piperazine compounds as inhibitors of btk activity
UA111756C2 (uk) * 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
WO2015000949A1 (en) 2013-07-03 2015-01-08 F. Hoffmann-La Roche Ag Heteroaryl pyridone and aza-pyridone amide compounds
WO2015050703A1 (en) * 2013-10-04 2015-04-09 Yi Chen Inhibitors of bruton's tyrosine kinase
RU2646758C2 (ru) 2013-12-05 2018-03-07 Ф. Хоффманн-Ля Рош Аг Гетероарил пиридоны и азапиридоны с электрофильной функциональностью
EP3201186B1 (en) 2014-10-02 2019-02-27 F. Hoffmann-La Roche AG Pyrazole carboxamide compounds for use in the treament of disorders mediated by bruton's tyrosine kinase (btk)
CN111747956A (zh) * 2014-10-27 2020-10-09 豪夫迈·罗氏有限公司 制备三环内酰胺化合物的方法
CN106188063A (zh) * 2015-05-08 2016-12-07 中国科学院上海药物研究所 用作Lp-PLA2抑制剂的双环类化合物、其制备方法及医药用途
UY36875A (es) 2015-09-02 2017-03-31 Glaxosmithkline Intellectual Property (No 2) Ltd Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
US10208024B2 (en) 2015-10-23 2019-02-19 Array Biopharma Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases
CN109071447B (zh) * 2016-02-19 2022-04-22 诺华股份有限公司 四环吡啶酮化合物作为抗病毒剂
CN113925833A (zh) * 2016-02-29 2022-01-14 豪夫迈·罗氏有限公司 包含酪氨酸蛋白激酶抑制剂的剂型组合物
WO2017186668A1 (en) * 2016-04-28 2017-11-02 F. Hoffmann-La Roche Ag A process for the preparation of 2-pyrazolo[1,5-a]pyrazin-2-ylpyrido[1,2-a]pyrimidin-4-one
CN108101905A (zh) * 2016-11-24 2018-06-01 中国科学院上海药物研究所 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途
AU2017368331A1 (en) 2016-12-03 2019-06-13 Acerta Pharma B.V. Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors
EP3551226A1 (en) 2016-12-12 2019-10-16 MultiVir Inc. Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
SG10202009148XA (en) * 2016-12-15 2020-10-29 Hoffmann La Roche Process for preparing btk inhibitors
KR102543603B1 (ko) 2016-12-22 2023-06-14 베타 파머수티컬 컴퍼니 리미티드 벤조이미다졸 유도체, 제조 방법 및 그것의 용도
EP3602058A1 (en) * 2017-03-24 2020-02-05 H. Hoffnabb-La Roche Ag Methods of treating autoimmune and inflammatory diseases
CN107445981B (zh) * 2017-08-25 2018-06-22 牡丹江医学院 一种用于防治宫颈炎的活性化合物
KR102613433B1 (ko) 2017-10-11 2023-12-13 주식회사 대웅제약 신규한 페닐피리딘 유도체 및 이를 포함하는 약학 조성물
US11440912B2 (en) 2017-10-27 2022-09-13 Fresenius Kabi Oncology Ltd Process for the preparation of ribociclib and its salts
US11100492B2 (en) 2018-02-19 2021-08-24 Peter Garrett General purpose re-loadable card aggregation implementation
US11702427B2 (en) 2018-03-12 2023-07-18 Arbutus Biopharma Corporation Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same
EP3789040A4 (en) 2018-04-27 2022-03-09 ONO Pharmaceutical Co., Ltd. PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASES WITH A COMPOUND WITH BTK INHIBITING ACTIVITY AS AN INGREDIENT
MA52809A (fr) 2018-06-07 2021-04-14 Disarm Therapeutics Inc Inhibiteurs de sarm1
JOP20210017A1 (ar) 2018-07-25 2021-01-21 Novartis Ag مثبطات جسيم التهابي nlrp3
KR102328682B1 (ko) 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
WO2020043321A1 (en) 2018-08-31 2020-03-05 Stichting Katholieke Universiteit Synergistic combinations of amino acid depletion agent sensitizers (aadas) and amino acid depletion agents (aada), and therapeutic methods of use thereof
AU2019360928B2 (en) 2018-10-15 2023-11-09 Nurix Therapeutics, Inc. Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
JP7212781B2 (ja) 2018-12-19 2023-01-25 ディスアーム セラピューティクス， インコーポレイテッド 神経保護剤と組み合わせたｓａｒｍ１の阻害剤
WO2020131674A1 (en) 2018-12-19 2020-06-25 Array Biopharma Inc. 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
CN113490666A (zh) 2018-12-19 2021-10-08 奥瑞生物药品公司 作为fgfr酪氨酸激酶的抑制剂的取代的吡唑并[1,5-a]吡啶化合物
TW202033523A (zh) * 2019-01-17 2020-09-16 美商愛彼特生物製藥股份有限公司 經取代的多環羧酸、其類似物及使用其之方法
CN118662512A (zh) 2019-01-22 2024-09-20 豪夫迈·罗氏有限公司 使用布鲁顿氏酪氨酸激酶抑制剂来治疗类风湿性关节炎、慢性自发性荨麻疹和系统性红斑狼疮的方法
EP3930717A1 (en) 2019-02-25 2022-01-05 Guangzhou Lupeng Pharmaceutical Company Ltd. Inhibitor of btk and mutants thereof
JP2022526713A (ja) 2019-03-21 2022-05-26 オンクセオ がんの処置のための、キナーゼ阻害剤と組み合わせたＤｂａｉｔ分子
WO2020210508A1 (en) 2019-04-09 2020-10-15 Nurix Therapeutics, Inc. 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus
UY38687A (es) 2019-05-17 2023-05-15 Novartis Ag Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso
US11530229B2 (en) 2019-05-17 2022-12-20 Nurix Therapeutics, Inc. Cyano cyclobutyl compounds for CBL-B inhibition and uses thereof
AU2020303696A1 (en) 2019-06-26 2022-01-06 Nurix Therapeutics, Inc. Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof
WO2021066958A1 (en) 2019-10-05 2021-04-08 Newave Pharmaceutical Inc. Inhibitor of btk and mutants thereof
WO2021091575A1 (en) * 2019-11-08 2021-05-14 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
CA3159348A1 (en) 2019-11-08 2021-05-14 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
CN115003304A (zh) 2019-12-04 2022-09-02 纽力克斯治疗公司 通过泛素蛋白酶体途径降解btk的双官能化合物
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN119925375A (zh) * 2020-02-20 2025-05-06 和记黄埔医药（上海）有限公司 杂芳基杂环化合物及其用途
BR112022017102A2 (pt) 2020-02-28 2022-11-16 Genentech Inc Métodos para tratar esclerose múltipla progressiva primária (ppms), retardar a progressão de ppms, retardar o início de pelo menos um evento de progressão em um indivíduo com ppms, reduzir o risco de um indivíduo com ppms ter pelo menos um evento de progressão e reduzir a deficiência em um indivíduo com ppms e compostos
JP2023520469A (ja) 2020-04-03 2023-05-17 ジェネンテック， インコーポレイテッド ブルトン型チロシンキナーゼの阻害剤を使用する再発性多発性硬化症の治療方法
US20230348471A1 (en) * 2020-06-18 2023-11-02 Shanghai Synergy Pharmaceutical Sciences Co., Ltd. Bruton's tyrosine kinase inhibitor and preparation method therefor
WO2022029068A1 (en) * 2020-08-04 2022-02-10 F. Hoffmann-La Roche Ag Pyridinone compounds for the treatment of autoimmune disease
IL299091A (en) 2020-08-14 2023-02-01 Novartis Ag Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof
KR20230051200A (ko) * 2020-08-14 2023-04-17 광조우 루펭 파마슈티칼 컴퍼니 엘티디. Btk 및 이의 돌연변이체의 억제제를 포함하는 투여 형태 조성물
JP2023542040A (ja) * 2020-09-21 2023-10-04 ハチソン メディファルマ リミテッド ヘテロアリール複素環化合物及びその使用
US20230382900A1 (en) 2020-10-30 2023-11-30 Newave Pharmaceutical Inc. Inhibitors of btk
EP4263552A1 (en) 2020-12-20 2023-10-25 Guangzhou Lupeng Pharmaceutical Company Ltd. Btk degrader
EP4313023A1 (en) 2021-04-02 2024-02-07 Biogen MA Inc. Combination treatment methods of multiple sclerosis
WO2022217123A2 (en) 2021-04-08 2022-10-13 Nurix Therapeutics, Inc. Combination therapies with cbl-b inhibitor compounds
ES3012969T3 (en) 2021-05-05 2025-04-10 Hoffmann La Roche Process for preparing btk inhibitors
CN113603685A (zh) * 2021-07-23 2021-11-05 都创(上海)医药开发有限公司 Fenebrutinib化合物的晶型及其制备方法和用途
IL312357A (en) 2021-10-26 2024-06-01 Nurix Therapeutics Inc Piperidinylpyrazine-carboxamide compounds for the treatment and prevention of cancer and to restore BTK
CA3241069A1 (en) 2021-12-14 2023-06-22 Adrianus Petrus Antonius De Man Macrocyclic btk inhibitors
WO2023137225A1 (en) * 2022-01-17 2023-07-20 Newave Pharmaceutical Inc. Btk degrader
TW202346276A (zh) 2022-01-27 2023-12-01 日商田邊三菱製藥股份有限公司 新穎之ｂ０ａｔ１抑制劑
EP4471012A1 (en) * 2022-01-28 2024-12-04 HUTCHMED Limited Synthesis method for 7,8-dihydro-2h-cyclopentapyrrolopyrazinone compound
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
WO2024238524A1 (en) 2023-05-16 2024-11-21 Genentech, Inc. Methods of treating relapsing multiple sclerosis using an inhibitor of bruton's tyrosine kinase
WO2024246287A1 (en) 2023-06-02 2024-12-05 Crossfire Oncology Holding B.V. Medical use of a macrocyclic reversible btk inhibitor
WO2024245578A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor
WO2024245577A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor
WO2024256568A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Salt and crystal forms of a macrocyclic btk inhibitor
WO2024256574A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Process for preparing macrocyclic btk inhibitors
WO2025031344A1 (zh) * 2023-08-07 2025-02-13 广州麓鹏制药有限公司 一种丙烯酰胺类化合物的晶型vi及其制备方法和用途

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
JPH08336393A (ja) 1995-04-13 1996-12-24 Mitsubishi Chem Corp 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
HRP20040130A2 (en) 2001-07-12 2004-10-31 Avecia Ltd Microencapsilated catalyst, methods of preparation and methods of use thereof
WO2005014599A1 (en) 2003-06-04 2005-02-17 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
US7393848B2 (en) 2003-06-30 2008-07-01 Cgi Pharmaceuticals, Inc. Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds
US20100190688A1 (en) 2004-07-12 2010-07-29 Bin Chao Tetrapeptide analogs
MX2007005643A (es) 2004-11-10 2008-03-13 Cgi Pharmaceuticals Inc Ciertas imidazo [1,2-a] pirazin-8-ilaminas, metodo para su elaboracion y metodo de uso de las mismas.
EP1863766B1 (en) 2005-03-10 2015-05-20 Gilead Connecticut, Inc. Certain substituted amides, method of making, and method of use thereof
US7803839B2 (en) 2005-10-07 2010-09-28 Exelixis, Inc. Azetidines as MEK inhibitors for the treatment of proliferative diseases
US7838523B2 (en) 2006-09-11 2010-11-23 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
AR063946A1 (es) 2006-09-11 2009-03-04 Cgi Pharmaceuticals Inc Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
AR063706A1 (es) 2006-09-11 2009-02-11 Cgi Pharmaceuticals Inc Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
CN101805341B (zh) * 2006-09-22 2013-07-24 药品循环公司 布鲁顿酪氨酸激酶的抑制剂
CL2008002793A1 (es) * 2007-09-20 2009-09-04 Cgi Pharmaceuticals Inc Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
CN101835755B (zh) * 2007-10-23 2013-12-11 霍夫曼-拉罗奇有限公司 激酶抑制剂
US8426441B2 (en) 2007-12-14 2013-04-23 Roche Palo Alto Llc Inhibitors of bruton's tyrosine kinase
US7683064B2 (en) 2008-02-05 2010-03-23 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
NZ586916A (en) * 2008-02-05 2012-06-29 Hoffmann La Roche Novel pyridinones and pyridazinones
JP5529852B2 (ja) 2008-05-06 2014-06-25 ジリード コネティカット，インコーポレイティド 置換アミド、その製造法及びＢｔｋインヒビターとしての使用
AU2009264400B2 (en) 2008-06-24 2014-05-01 F. Hoffmann-La Roche Ag Novel substituted pyridin-2-ones and pyridazin-3-ones
DK2300459T3 (da) 2008-07-02 2013-09-02 Hoffmann La Roche Nye fenylpyrazinoner som kinasehæmmere
CA2636807A1 (en) 2008-07-04 2010-01-04 Steven Splinter Methods for obtaining cyclopamine
JP5318952B2 (ja) 2008-07-15 2013-10-16 エフ．ホフマン−ラ ロシュ アーゲー 新規なフェニル−イミダゾピリジン類及びピリダジン類
US8598174B2 (en) 2008-11-12 2013-12-03 Genetech, Inc. Pyridazinones, method of making, and method of use thereof
US8299077B2 (en) * 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
CN102292329B (zh) * 2009-04-24 2014-09-03 霍夫曼-拉罗奇有限公司 布鲁顿酪氨酸激酶的抑制剂
WO2010126960A1 (en) * 2009-04-29 2010-11-04 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
PT2473049T (pt) * 2009-09-04 2019-03-04 Sunesis Pharmaceuticals Inc Inibidores de tirosina quinase de bruton
RU2617405C2 (ru) * 2010-05-07 2017-04-25 Джилид Коннектикут, Инк. Пиридоновые и азапиридоновые соединения и способы применения
AR082590A1 (es) * 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
BR112013007499A2 (pt) 2010-09-01 2016-07-12 Genentech Inc piridazinonas - métodos de criação e usos
WO2012031004A1 (en) 2010-09-01 2012-03-08 Gilead Connecticut, Inc. Pyridinones/pyrazinones, method of making, and method of use thereof
BR112013029620A2 (pt) 2011-05-17 2016-09-06 Hoffmann La Roche inibidores de tirosina quinase de bruton
EA024689B1 (ru) * 2011-08-17 2016-10-31 Ф.Хоффманн-Ля Рош Аг Ингибиторы тирозинкиназы брутона
PH12014500966A1 (en) * 2011-11-03 2014-06-09 Hoffmann La Roche Alkylated piperazine compounds as inhibitors of btk activity
UA111756C2 (uk) * 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
BR112014010460A2 (pt) * 2011-11-03 2017-04-18 Hoffmann La Roche composto, composição farmacêutica, processo para produzir uma composição farmacêutica, método de tratamento, kit e uso de uma composição farmacêutica
WO2015000949A1 (en) * 2013-07-03 2015-01-08 F. Hoffmann-La Roche Ag Heteroaryl pyridone and aza-pyridone amide compounds
RU2646758C2 (ru) * 2013-12-05 2018-03-07 Ф. Хоффманн-Ля Рош Аг Гетероарил пиридоны и азапиридоны с электрофильной функциональностью
CN113925833A (zh) * 2016-02-29 2022-01-14 豪夫迈·罗氏有限公司 包含酪氨酸蛋白激酶抑制剂的剂型组合物

Also Published As

Publication number Publication date
AU2012332365A1 (en) 2014-05-01
TW202124384A (zh) 2021-07-01
HK1201265A1 (en) 2015-08-28
TWI701250B (zh) 2020-08-11
ES2555168T3 (es) 2015-12-29
TW201326175A (zh) 2013-07-01
US8921353B2 (en) 2014-12-30
RS54505B1 (sr) 2016-06-30
EP3002284A1 (en) 2016-04-06
PL3521288T3 (pl) 2021-12-27
EA023263B1 (ru) 2016-05-31
AU2019216728B2 (en) 2020-04-09
KR20140096097A (ko) 2014-08-04
MX2014005331A (es) 2014-05-28
EP3002284B1 (en) 2019-05-22
EP2773638A1 (en) 2014-09-10
CR20140194A (es) 2014-06-03
JP2014532762A (ja) 2014-12-08
EP2773638B1 (en) 2015-10-07
PT2773638E (pt) 2016-01-12
AU2020202707B2 (en) 2021-09-02
SI2773638T1 (sl) 2015-12-31
AR117501A2 (es) 2021-08-11
AR088641A1 (es) 2014-06-25
US20210079002A1 (en) 2021-03-18
DK3002284T3 (da) 2019-07-29
US20140194408A1 (en) 2014-07-10
US8716274B2 (en) 2014-05-06
PE20141586A1 (es) 2014-10-25
AU2012332365B2 (en) 2016-09-15
ES2898938T3 (es) 2022-03-09
US9238655B2 (en) 2016-01-19
USRE48239E1 (en) 2020-10-06
MA35819B1 (fr) 2014-12-01
ZA201804727B (en) 2023-03-29
DK2773638T3 (en) 2015-10-19
CA2853975A1 (en) 2013-05-10
RS59016B1 (sr) 2019-08-30
PL3002284T3 (pl) 2019-11-29
EA201490858A1 (ru) 2014-08-29
JP5976827B2 (ja) 2016-08-24
TW201741315A (zh) 2017-12-01
BR112014010459A2 (pt) 2017-04-18
US20130116235A1 (en) 2013-05-09
US10045983B2 (en) 2018-08-14
LT3002284T (lt) 2019-08-12
KR20160003328A (ko) 2016-01-08
EP3521288A1 (en) 2019-08-07
EP3521288B1 (en) 2021-09-08
TR201909849T4 (tr) 2019-07-22
US20160228432A1 (en) 2016-08-11
IN2014CN03250A (en:Method) 2015-07-03
EP4050012A1 (en) 2022-08-31
US20240270747A1 (en) 2024-08-15
US9782405B2 (en) 2017-10-10
CN107011348B (zh) 2020-01-10
JP6571215B2 (ja) 2019-09-04
IL232060A0 (en) 2014-05-28
JP2016028046A (ja) 2016-02-25
TW201906845A (zh) 2019-02-16
US20230279012A1 (en) 2023-09-07
JP2018080193A (ja) 2018-05-24
PH12014500936A1 (en) 2014-06-09
WO2013067274A1 (en) 2013-05-10
UA111756C2 (uk) 2016-06-10
ES2738329T3 (es) 2020-01-22
CO6950472A2 (es) 2014-05-20
SI3002284T1 (sl) 2019-08-30
PT3002284T (pt) 2019-07-17
EP4019508A1 (en) 2022-06-29
HRP20191307T1 (hr) 2019-10-18
US20200062769A1 (en) 2020-02-27
US20140378432A1 (en) 2014-12-25
JP2020183397A (ja) 2020-11-12
CY1117097T1 (el) 2017-04-05
HUE028019T2 (en) 2016-11-28
HUE044959T2 (hu) 2019-12-30
SG11201401992YA (en) 2014-05-29
AU2016273930B2 (en) 2018-03-08
AU2020202707A1 (en) 2020-05-14
AU2018201557A1 (en) 2018-03-22
CL2014001103A1 (es) 2014-10-03
CN107011348A (zh) 2017-08-04
JP2019108342A (ja) 2019-07-04
CA2853975C (en) 2020-02-25
AU2016273930A1 (en) 2017-01-12
TWI609868B (zh) 2018-01-01
HRP20151442T1 (hr) 2016-01-29
AU2019216728A1 (en) 2019-09-05
CN104125959B (zh) 2017-05-03
AU2018201557B2 (en) 2019-09-19
MX361807B (es) 2018-12-17
NZ624021A (en) 2016-09-30
KR101659193B1 (ko) 2016-09-22
US20180071286A1 (en) 2018-03-15
US20190194203A1 (en) 2019-06-27
TWI652270B (zh) 2019-03-01
CN104125959A (zh) 2014-10-29
IL232060A (en) 2016-02-29

Similar Documents

Publication Publication Date Title
ZA201804727B (en) Heteroaryl pyridone and aza-pyridone compounds as inhibitors of btk activity
IL266168A (en) Heteroaryl compounds and methods of their use
ZA201209205B (en) Pyridone and aza-pyridone compounds and methods of use
IL238409A0 (en) Heteroaryl inhibitors of pde4
ZA201307632B (en) Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
ZA201403158B (en) Alkylated piperazine compounds as inhibitors of btk activity
ZA201303793B (en) Substituted quinoline compounds and methods of use
ZA201401653B (en) Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use
EP2758387A4 (en) Pyridine compounds as kinase inhibitors
EP2709999A4 (en) QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE
ZA201408856B (en) Heteroaryl compounds and methods of use thereof
IL232170A0 (en) Heterocyclic carboxamides are useful as phosphodiesterase type 10a inhibitors
TH1401002406B (th) สารประกอบเฮทเทอโรเอริล ไพริโดน และ อะซา-ไพริโดนในรูปสารยับยั้งของ btk แอคตีวิตี้
HK1191650A (en) Picolinamide inhibitors of kinases